ANDREW JOHNSON: Open Payments
NPI 1730778978 · COSTA MESA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,545 in 210 payments from 21 companies in 2025. Trend: 2023 $5,890 · 2024 $5,120 · 2025 $4,545
Food & beverage: $4,545
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 33 | $637 |
| Neurocrine BioSciences, Inc. | 24 | $553 |
| ABBVIE INC. | 26 | $550 |
| Vanda Pharmaceuticals Inc. | 22 | $487 |
| E.R. Squibb & Sons, L.L.C. | 14 | $327 |
| Janssen Pharmaceuticals, Inc | 8 | $317 |
| Otsuka America Pharmaceutical, Inc. | 12 | $264 |
| Alkermes, Inc. | 9 | $242 |
| Lundbeck LLC | 11 | $193 |
| Noven Therapeutics, LLC | 9 | $189 |
Products named: CAPLYTA, INGREZZA, VRAYLAR, FANAPT, COBENFY, REXULTI, SPRAVATO, ARISTADA.
Industry payments across CA — which companies pay providers there.
